Clinical Data, Inc. Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Newton MA United States (1969)
Status: Acquired by Forest Laboratories (2011) → now AbbVie (2019)

Organization Overview

First Clinical Trial
1982
NCT00000504
First Marketed Drug
2011
vilazodone (viibryd)
First NDA Approval
2011
vilazodone (viibryd)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Clinical Data, Inc

Active Ingredients

Marketed Drugs (1)

Key: Clinical Data, Inc. (0) Acquired (1)

vilazodone (viibryd) (2011 NDA)

Drugs in Phase 3 Trials (1)

Key: Clinical Data, Inc. (0) Acquired (1)

vilazodone (viibryd) (1 trial)

Drugs in Phase 2 Trials (4)

encainide (Enkaid) (1 trial)

flecainide (tambocor) (1 trial)

imipramine (tofranil) (1 trial)

moricizine (ethmozine) (1 trial)

Indications

Approved Indications


 

Depressive Disorder, Major

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 2)

Heart Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 5